+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Randomized phase Iii study of mitomycin/vindesine/cisplatin (Mvp) versus weekly irinotecan/carboplatin (Ic) or weekly paclitaxel/carboplatin (Pc) with concurrent thoracic radiotherapy (Ctr) for patients (pts) with unresectable stage Iii non-small cell lung cancer (Nsclc): West Japan Thoracic Oncology Group (Wjtog) 0105



Randomized phase Iii study of mitomycin/vindesine/cisplatin (Mvp) versus weekly irinotecan/carboplatin (Ic) or weekly paclitaxel/carboplatin (Pc) with concurrent thoracic radiotherapy (Ctr) for patients (pts) with unresectable stage Iii non-small cell lung cancer (Nsclc): West Japan Thoracic Oncology Group (Wjtog) 0105



European Journal of Cancer Suppl.s 7(2): 535-536




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067144581

Download citation: RISBibTeXText

DOI: 10.1016/s1359-6349(09)71817-8


Related references

C3-03: Randomized, phase Iii Study of mitomycin/vindesine/cisplatin (Mvp) versus weekly irinotecan/carboplatin (Ic) or weekly paclitaxel/carboplatin (Pc) with concurrent thoracic radiotherapy (Trt) for unresectable stage Iii non-small-cell lung cancer (Nsclc): Wjtog0105. Journal of Thoracic Oncology 2(8): S365-S366, 2007

Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Annals of Oncology 28(4): 777-783, 2017

A randomized phase Iii study of concurrent versus sequential thoracic radiotherapy (Trt) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage Iii non-small cell lung cancer (Nsclc): Preliminary analysis. Lung Cancer 18: 76-77, 1997

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: A California cancer consortium phase II trial. Journal of Clinical Oncology 19(2): 442-447, 2001

A phase II study of induction chemotherapy with irinotecan and cisplatin followed by thoracic radiotherapy combined with weekly CPT-11 in patients with unresectable stage III non-small cell lung cancer Final results of Japan Clinical Oncology Group 9706. International Journal of Cancer Suppl. (13): 438, 2002

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. British Journal of Cancer 87(3): 258-263, 2002

A phase Ii trial of individualized response-based induction chemotherapy (Ic) of mitomycin-C, vindesine, cisplatin (Mvp) followed by thoracic radiotherapy (Trt) with daily low-dose carboplatin (Cbdca) for the treatment of unresectable stage Iii non-small-cell lung cancer (Nsclc). Lung Cancer 29(1): 110-111, 2000

Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Journal of Thoracic Oncology 3(3): 250-257, 2008

Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. Journal of Thoracic Oncology 6(3): 553-558, 2011

Randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of West Japan Thoracic Oncology Group 0004. Journal of Clinical Oncology 24(18_Suppl): 7151-7151, 2016

Phase II study of induction chemotherapy with gemcitabine and carboplatin (IndGC) followed by paclitaxel and carboplatin with concurrent thoracic radiation (PCRT) for patients with unresectable stage III non-small-cell lung cancer (NSCLC): MCC-13240. Journal of Clinical Oncology 23(16_Suppl): 7307-7307, 2016

Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 77(1): 89-96, 2012

Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902. Yearbook of Oncology 2008: 171-173, 2008

Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. Journal of Clinical Oncology 24(33): 5247-5252, 2006

Induction carboplatin-paclitaxel-gemcitabine followed by concurrent weekly carboplatin-paclitaxel and radiation therapy in unresectable stage III non-small cell lung cancer A phase II Study. EJC Suppl.s 1(5): S246, 2003